Fresh analysis reveals that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who halt conventional diet and exercise plans.
Published data in a prominent health publication points out that while obese individuals frequently drop a large proportion of their body weight while on the medication, the weight comes back at an average rate of nearly a kilo each month once they quit.
"Individuals buying these treatments should be aware of the potential of rapid weight regain when the medication ends," warns expert Dr. Susan Jebb.
That rate of regain implies a return to starting weight in about one and a half years.
Analyzing Therapies
The study, which reviewed dozens of studies involving over 9,000 of participants, contrasted the outcomes of GLP-1 agonists with conventional dieting.
Researchers note that individuals who lose weight through lifestyle changes alone generally see a slower weight regain—perhaps 100 grams monthly—once they finish.
The Reason for the Rapid Rebound
Experts suggest the mechanism of the drugs accounts for the accelerated weight return.
These medications copy a natural hormone called GLP-1, which controls appetite.
"Sustained high doses of the hormone levels several times higher than the body's typical production may cause the system to produce less of its own natural hormone, and could diminish responsiveness to its effects," said Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' leads to hunger is no longer kept in check, making binge eating far more likely."
A Lifelong Disease?
The NHS recommend the injections for individuals with weight-linked medical conditions, alongside recommended lifestyle changes.
A number of clinicians contend that, considering the high risk of weight regain, the treatment might need to be long-term.
This opinion is echoed by pharmaceutical companies, who state that the findings "emphasize the persistent nature of excess weight," akin to managing diseases like diabetes.
User Experiences
Users who have discontinued the jabs describe a intense resurgence of appetite.
"It was like something that goes on and I was suddenly extremely hungry," recalled an individual.
The struggle is compounded if users have not developed sustainable lifestyle or habit changes during therapy.
Widespread Use
Recent estimates suggest that a significant number of adults in the UK have used weight-loss jabs in the past year, with demand being substantial.
- Adoption is more common among women than men.
- The middle-aged age group shows the highest level of interest.
- Many obtain the drugs through private healthcare rather than public health services.
In conclusion, clinicians caution that while GLP-1 drugs are effective agents for shedding pounds, they are not a permanent fix and long-term success likely depends on combined lifestyle management.
